Cargando…
Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease
Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD)....
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658500/ https://www.ncbi.nlm.nih.gov/pubmed/34884205 http://dx.doi.org/10.3390/jcm10235498 |
_version_ | 1784612747354308608 |
---|---|
author | Naruse, Hiroyuki Ito, Hiroyasu Izawa, Hideo Sarai, Masayoshi Ishii, Junnichi Sakaguchi, Eirin Murakami, Reiko Ando, Tatsuya Fujigaki, Hidetsugu Saito, Kuniaki |
author_facet | Naruse, Hiroyuki Ito, Hiroyasu Izawa, Hideo Sarai, Masayoshi Ishii, Junnichi Sakaguchi, Eirin Murakami, Reiko Ando, Tatsuya Fujigaki, Hidetsugu Saito, Kuniaki |
author_sort | Naruse, Hiroyuki |
collection | PubMed |
description | Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection. |
format | Online Article Text |
id | pubmed-8658500 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86585002021-12-10 Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease Naruse, Hiroyuki Ito, Hiroyasu Izawa, Hideo Sarai, Masayoshi Ishii, Junnichi Sakaguchi, Eirin Murakami, Reiko Ando, Tatsuya Fujigaki, Hidetsugu Saito, Kuniaki J Clin Med Article Concern has been raised about the effectiveness of the coronavirus disease 2019 (COVID-19) vaccine in the population of patients with various comorbidities such as heart disease. We investigated the humoral response to the BNT162b2 mRNA COVID-19 vaccine in patients with cardiovascular disease (CVD). We measured IgG against severe acute respiratory syndrome coronavirus 2 spike receptor-binding domain (RBD-IgG) in 85 CVD patients and 179 healthcare workers (HCWs). Blood samples were collected from patients and HCWs three times: (1) before the first dose of vaccination, (2) two weeks after the first dose of vaccination, and (3) two weeks after the second dose of vaccination. Patients with CVD showed a significantly inferior serological response to the BNT162b2 mRNA COVID-19 vaccine at 14 days after the prime dose compared to HCWs (21% vs. 95%, p < 0.001). Median RBD-IgG titers of patients with CVD at 14 days after the second dose were significantly lower than those of HCWs (137.2 U/mL (80.6–200.4 U/mL) vs. 176.2 U/mL (123.9–260.0 U/mL), p < 0.001). In multivariable analyses, CVD is significantly associated with seropositivity after first vaccination and RBD-IgG titers after second vaccination. CVD patients may have a poor humoral response to the BNT162b2 mRNA COVID-19 vaccine, need to be closely monitored, and require earlier revaccination to ensure stronger immunity and protection against infection. MDPI 2021-11-24 /pmc/articles/PMC8658500/ /pubmed/34884205 http://dx.doi.org/10.3390/jcm10235498 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Naruse, Hiroyuki Ito, Hiroyasu Izawa, Hideo Sarai, Masayoshi Ishii, Junnichi Sakaguchi, Eirin Murakami, Reiko Ando, Tatsuya Fujigaki, Hidetsugu Saito, Kuniaki Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease |
title | Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease |
title_full | Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease |
title_fullStr | Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease |
title_full_unstemmed | Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease |
title_short | Immunogenicity of BNT162b2 mRNA COVID-19 Vaccine in Patients with Cardiovascular Disease |
title_sort | immunogenicity of bnt162b2 mrna covid-19 vaccine in patients with cardiovascular disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658500/ https://www.ncbi.nlm.nih.gov/pubmed/34884205 http://dx.doi.org/10.3390/jcm10235498 |
work_keys_str_mv | AT narusehiroyuki immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT itohiroyasu immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT izawahideo immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT saraimasayoshi immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT ishiijunnichi immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT sakaguchieirin immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT murakamireiko immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT andotatsuya immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT fujigakihidetsugu immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease AT saitokuniaki immunogenicityofbnt162b2mrnacovid19vaccineinpatientswithcardiovasculardisease |